Summary of Purpose
To establish the highest safe and tolerated loading and maintenance dosing regimen of AR-R15896AR in acute ischemic stroke patients and to determine the plasma concentrations of AR-R15896AR with which these were associated.Read More →
The following dates are available for this trial. Trial information last updated on 9 February 2001.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
Double-blind, randomized, placebo-controlled trial of 175 patients at 5 centers. The trial consisted of four parts: Part 1; a series of increasing loading doses. Part 2; a comparison of selected doses from part 1. For parts 3 and 4 of this study, the loading dose was fixed for all subjects receiving active drug.
Prof Kennedy R. Lees, University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow G11 6NT, UK.firstname.lastname@example.org